Pfizer Inc. has announced positive top-line safety and immunogenicity data from a substudy of its ongoing Phase 3 MONeT trial evaluating ABRYSVO for the prevention of respiratory syncytial virus (RSV) in immunocompromised adults. The data showed a single dose of the vaccine was well-tolerated and generated a strong immune response across various immunocompromised patient groups.   The substudy enrolled 203 adults with conditions such as cancer, kidney disease, autoimmune disorders, and organ t...